Priming effect of dextran sulphates on lipopolysaccharide-induced tumour necrosis factor production in mice.
Dextran sulphate (DS) 500 (M.W. 500,000) is commonly used as a reticuloendothelial (RE) blocker. We found that lipopolysaccharide (LPS)-induced tumour necrosis factor (TNF) production in sera was enhanced when mice were pretreated with DS500. When mice were pretreated with DS1000 (M.W. 1,000,000), TNF activity in sera was also significantly enhanced by the LPS injection in comparison with the saline-treated group, but not by the pretreatment with the low molecular weight of DS5 (M.W. 5,000), neutral dextran (Dex) 500, or positively-charged diethylaminoethyl dextran (DEAE-Dex) 500. The enhancement of LPS-induced TNF production occurred from 2 h after DS500 pretreatment. Pretreatment with DS500 or DS1000 significantly suppressed the carbon clearance from the blood in mice from 2 h after DS injection, but this suppression was not detected by the pretreatment with DS5, Dex500, or DEAE-Dex500. We suggest that negative-charge and high molecular weight are essential for dextran derivatives to enhance LPS-induced TNF production, and that the enhancing effect of DS is closely related to the suppression of the RE function.
Kamochi
M
M
Intensive Care Unit, Hospital and School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Ogata
M
M
Yoshida
S
S
Mizuguchi
Y
Y
Shigematsu
A
A
D000818:Animals; D002244:Carbon / Q000493:pharmacokinetics; D016264:Dextran Sulfate / Q000494:pharmacology*; D004306:Dose-Response Relationship, Immunologic; D008070:Lipopolysaccharides / Q000276:immunology*; D008297:Male; D008657:Metabolic Clearance Rate; D051379:Mice; D012157:Mononuclear Phagocyte System / Q000187:drug effects; D010587:Phagocytosis; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis*
D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha; D002244:Carbon; D016264:Dextran Sulfate